Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
Tankyrase-1 [1]
(Cell-free assay)
1 nM 5 nM 1.5 μM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j2W|Qh\A>? NFzxRWRKSzVyPUWuO|A2KCEQvF2g NVewfWxqOTh3NUm2NVM>
KP6.3 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe0JIQ> NFT2dVZKSzVyPUGwMlQzQCEQvF2g NFfhcoYyQDV3OU[xNy=>
KP7.7 NXfJW5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhO3A1KGR? NWi5NnptUUN3ME21O{BvVSB? Mo[wNVg2PTl4MUO=
KB2P3.4 M3jpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi3OEBl NFjze41KSzVyPUGyOEBOKA>? NHfLPY4yQDV3OU[xNy=>
KB2P1.21 M4nRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DyW|Qh\A>? MoXaTWM2OD16OUC3JI5OKA>? M163OVE5PTV7NkGz
U373-MG NEPPelhEgXSxdH;4bYMhSXO|YYm= NGPKSo0yKM7:TTC= Mn22NlQhcA>? NFm1RoxKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NWLZR4hbOTh7NUS3NVI>
T98G M4\JVGN6fG:2b4jpZ{BCe3OjeR?= NH3FOJQyKM7:TTC= M{XVOlI1KGh? MYXJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 MY[xPFk2PDdzMh?=
U87-MG NYnPNWc6S3m2b4TvfIlkKEG|c3H5 NXf3dXY2OSEQvF2g MWeyOEBp MVLJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M3LY[lE5QTV2N{Gy
UVW MkTnR5l1d3SxeHnjJGF{e2G7 MWO1NFAhdk1? NVSxdodEOjRiaB?= NGHu[JJKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 Mnr5NVg6PTR5MUK=
HeLa M4jvZmZ2dmO2aX;uJGF{e2G7 M2q5UVUxOCCwTR?= MnXOOEBp NXLmcpZ3S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NFHBeIwyQDl3NEexNi=>
HeLa NHjiW|ZHfW6ldHnvckBCe3OjeR?= NHz0Z|gyKM7:TTC= MmfaNlQhcA>? NFXrdZNGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= NYrHNGR{OTh7NUS3NVI>
T98G NHvnb3FHfW6ldHnvckBCe3OjeR?= MXGxJO69VSB? MYmyOEBp M1zDc2VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 M3LXdFE5QTV2N{Gy
L3 Mn30R5l1d3SxeHnjJGF{e2G7 M3\6VVUh|ryPIB?= MUS5OkBp NWfuTlNXTE2VTx?= NVK3VpN4W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MUCyNFEzPDR3OR?=
Granta-519 Mn7PR5l1d3SxeHnjJGF{e2G7 NGXpXlE2KM7:TTC= M1jENlk3KGh? M4rJNGROW09? NWO2VHh2W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NUjRXJo5OjBzMkS0OVk>
BT NUHlbItCS3m2b4TvfIlkKEG|c3H5 M{HCUFUh|ryPIB?= NHvPUpg6PiCq NVvEVZBmTE2VTx?= MkLzV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NIS5OVkzODF{NES1PS=>
UPN2 M{\lTmN6fG:2b4jpZ{BCe3OjeR?= NVjKN29EPSEQvF2g NVPuUoV{QTZiaB?= NXLZcmh{TE2VTx?= MW\TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M1XIeFIxOTJ2NEW5
HBL-2 M1jSRmN6fG:2b4jpZ{BCe3OjeR?= Mn;YOUDPxE1i NFnnVXk6PiCq NVy3SJN1TE2VTx?= MYXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NWrBUYhtOjBzMkS0OVk>
JVM-2 MnHKR5l1d3SxeHnjJGF{e2G7 MUC1JO69VSB? NFjUOoE6PiCq Ml7GSG1UVw>? Ml\qV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NIS0WHQzODF{NES1PS=>
Z138 M1LocWN6fG:2b4jpZ{BCe3OjeR?= NImwdWM2KM7:TTC= MVi5OkBp NV22cnk3TE2VTx?= M3GzPXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M2DRcVIxOTJ2NEW5
RWPE M37sc2lvfmG|aY\lJGF{e2G7 M{fQZ|I2KM7:TR?= MlzkOFghcA>? MnPSSG1UVw>? NVXaO2pHW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? MX6yNVU4PTh4NR?=
VCaP NF3qZpNKdn[jc3n2[UBCe3OjeR?= NVvyU5pUOjVizszN NF\sdFE1QCCq MVPEUXNQ NEPYZnBUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NVfMS5RPOjF3N{W4OlU>
Mouse H2AX−/− ES Cells NYHq[3JqS3m2b4TvfIlkKEG|c3H5 NFTEPIEzNjVizszN NVfRZYxnOjBiaB?= NELXOo9UcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> MoC5NlM{PTV2OEm=
Mouse ATM−/− ES Cells NYf2fnlyS3m2b4TvfIlkKEG|c3H5 Mnf6Nk42KM7:TR?= NXjTbpFDOjBiaB?= NWDmRWR6W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NVrBXJU6OjN|NUW0PFk>
H1650 NVz6SYdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjiNlAh|ryP MXWxOFQhcA>? M4\IcWlEPTB;MUWuOFch|ryP MXKyN|I{QThyOR?=
H1650PTEN+ M{LDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmyNEDPxE1? NUPrUFRkOTR2IHi= Mmq0TWM2OD13MD64N{DPxE1? M1n0UlI{OjN7OEC5
PC-9 NFH4d|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPiVGwzOCEQvF2= MkDyNVQ1KGh? NHL4XWVKSzVyPUWuPFgh|ryP Mlz4NlMzOzl6MEm=
PC-9PTEN− MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPXNlAh|ryP Mkf4NVQ1KGh? NWm5OnNkUUN3ME22MlUzKM7:TR?= M3;velI{OjN7OEC5
MDA-MB-231 NID4V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\QTVUh\GG7 MYfJR|UxRTZwOTFOwG0> MmW1NlM4PjB2OU[=
MDA-MB-468 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjLfJg2KGSjeR?= M{PSPWlEPTB;NT6wJO69VQ>? Mnr4NlM4PjB2OU[=
BT20 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRfFUh\GG7 MV3JR|UxRTdwNzFOwG0> MYOyN|c3ODR7Nh?=
HCC1143 NX\jU5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK4WXo2KGSjeR?= Moj1TWM2OD1zMT6xJO69VQ>? M4DtTVI{PzZyNEm2
HCC1937 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV21JIRigQ>? MVHJR|UxRTF{Lk[g{txO MWKyN|c3ODR7Nh?=
Hs578t MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zXd|Uh\GG7 M3\2XmlEPTB;NT62JO69VQ>? MnTwNlM4PjB2OU[=
Hs578t(si) MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH36Wow2KGSjeR?= M1THT2lEPTB;Nz61JO69VQ>? MkT6NlM4PjB2OU[=
BT474 M{\pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzuXZY2KGSjeR?= M3q3NWlEPTB;MUmuPEDPxE1? M2HlfVI{PzZyNEm2
JIMT1 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O0N|Uh\GG7 NUPsTIJNUUN3ME23Mlch|ryP NF\CeXAzOzd4MES5Oi=>
SKBR3 NHnjeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLVlUh\GG7 MXvJR|UxRTFzLkGg{txO NF7QbVkzOzd4MES5Oi=>
SUM159 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPUWpNyPSCmYYm= NIPHPJhKSzVyPUSuNkDPxE1? M3TvclI{PzZyNEm2
CAMA1 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnuWJM2KGSjeR?= MX\JR|UxRTF3Lkig{txO NH\Nb2YzOzd4MES5Oi=>
MCF7 NXvxRZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrDcHdZPSCmYYm= MWTJR|UxRTVwODFOwG0> MYiyN|c3ODR7Nh?=
T47D M3z0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\te|k2KGSjeR?= M2TzVGlEPTB;OT62JO69VQ>? MXuyN|c3ODR7Nh?=
HCT116 NWTTdHJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXENVAxKM7:TR?= M{D6clQ5KGh? NXnQR48yTE2VTx?= MW\JR|UxRTJwNTFOwG0h MUKyOFU4Pzl2MR?=
SW1116 NWPyclhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxNFAh|ryP M{j2SFQ5KGh? MmnRSG1UVw>? NHrsXnVKSzVyPUGwNEDPxE1? Mo\WNlQ2Pzd7NEG=
HT29 M32w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLJNVAxKM7:TR?= MUG0PEBp M13UZWROW09? MlrzTWM2OD1zND63JO69VQ>? MVuyOFU4Pzl2MR?=
LoVo NF7RSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrs[5hkOTByIN88US=> MljsOFghcA>? NXnNZmtUTE2VTx?= MYPJR|UxRTF|LkSg{txO M4fme|I1PTd5OUSx
HCT-15 M2W5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HGSVExOCEQvF2= MnHiOFghcA>? NY\KWm9JTE2VTx?= MkHYTWM2OD1zMDFOwG0> NF;jVo4zPDV5N{m0NS=>
SW48 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXlNVAxKM7:TR?= MVy0PEBp MmDVSG1UVw>? MXzJR|UxRTlwNTFOwG0> NX76dpVlOjR3N{e5OFE>
C-1 NEHtRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUPFgyODBizszN NEPnNHk1QCCq NHTV[WRFVVOR NWHQTY9nUUN3ME23MlYh|ryP NGXXZnczPDV5N{m0NS=>
RKO MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvPSGF7OTByIN88US=> MoTkOFghcA>? M2TwPGROW09? NXKzcWdKUUN3ME21Mlkh|ryP NFXocHozPDV5N{m0NS=>
HCT116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3oXJZuOTByIN88US=> NYTQWFNvPDhiaB?= M4rFfmROW09? NV\6fYE6WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MXuyOFU4Pzl2MR?=
SW1116 NEXEUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4NVAxKM7:TR?= MY[0PEBp NVG2SZFlTE2VTx?= Ml7UVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MnTHNlQ2Pzd7NEG=
HT29 NVzJR21JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDGNVAxKM7:TR?= NFrIVo81QCCq MoP0SG1UVw>? MY\Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NGTWO4czPDV5N{m0NS=>
LoVo NIO3ZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWey[WhnOTByIN88US=> MXq0PEBp MYHEUXNQ Mn[xVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M1vy[VI1PTd5OUSx
SW48 M3Lkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAh|ryP M4XwTlQ5KGh? M3jLbWROW09? MYTQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MYqyOFU4Pzl2MR?=
C-1 M2jr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLWNVAxKM7:TR?= MX20PEBp NVvKXHYyTE2VTx?= NFvJd5lRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MU[yOFU4Pzl2MR?=
RKO NV3xSHd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDVWVcyODBizszN MXy0PEBp MmHlSG1UVw>? NF7QTHFRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NF7y[JczPDV5N{m0NS=>
HCT116 M2XN[mZ2dmO2aX;uJGF{e2G7 NVn3Z|BEOTBibl2= Ml:4NVIhcA>? NIjneWJFVVOR MX7JcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? NV;KUINUOjR3N{e5OFE>
HT29 MmTYSpVv[3Srb36gRZN{[Xl? NYrzdXBIOTBibl2= MomyNVIhcA>? MVvEUXNQ M1fsVmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= NXnCWnBYOjR3N{e5OFE>
TE-6 M{DRTGZ2dmO2aX;uJGF{e2G7 MlXUOUDPxE1i NWe0NHlvOTJiaB?= NH7mZ5FFVVOR M3nONWlv\HWlZYOgS|IwVSCjcoLld5Q> MVOyOFIyQTF4NB?=
TE-6 M1jxRWZ2dmO2aX;uJGF{e2G7 MVW1JO69VSB? Mn;pNlQhcA>? NVH5fGx7TE2VTx?= MnL5TY5kemWjc3XzJIlvKGSxdXLs[UB{fHKjbnSgZpJm[Wu|IDjEV2J{MQ>? MVeyOFIyQTF4NB?=
Hep3B MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\DWZI1OCEQvF2g NH3lVXM4OiCq M1XEeWROW09? MVrTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> NVHZZWJTOjVyN{K3OVI>
Huh7 NEHtfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3XYc1OCEQvF2g MnXqO|IhcA>? MmPXSG1UVw>? MkHxV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> NHn2V|AzPTB5Mke1Ni=>
Hep3B M{j6[mZ2dmO2aX;uJGF{e2G7 MWG0NEDPxE1i MmLtNlQhcA>? NUCxd|lDTE2VTx?= M1rmTmlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= M4exUlI2ODd{N{Wy
Huh7 NX7FUWJRTnWwY4Tpc44hSXO|YYm= MXy0NEDPxE1i MnW1NlQhcA>? NUT0fppnTE2VTx?= MYXJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NIDtUZEzPTB5Mke1Ni=>
Hep3B M2DRZ2Z2dmO2aX;uJGF{e2G7 M3HoSVQxKM7:TTC= M4P3NlI1KGh? M4HtTmROW09? NWW3VVNxUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR MYmyOVA4Ojd3Mh?=
Huh7 NHrZNVBHfW6ldHnvckBCe3OjeR?= NXPQTFRlPDBizszNJC=> M3HhZlI1KGh? NV6wcnhmTE2VTx?= MmHDTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MlfINlUxPzJ5NUK=
SGC-7901 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmxN2YzOzEEoN88US=> NED3dHI1QCCq M3nCRWROW09? NHKzO|VDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MlzYNlU4PjdyN{[=
COLO-800 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlUWlEPTB;MD60OFE3PCEQvF2= Mnf1V2FPT0WU
EoL-1- NF3LPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjLO5pvUUN3ME2wMlU3PDR4IN88US=> MofUV2FPT0WU
NCI-H209 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwOUG1OVYh|ryP Mmr6V2FPT0WU
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvUTWM2OD1zLkGxOFA5KM7:TR?= Mn3TV2FPT0WU
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvnTWM2OD1zLkK1N|Q4KM7:TR?= NF3afpJUSU6JRWK=
NTERA-S-cl-D1 NW\uNFZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPLTWM2OD1zLkOzN|QyKM7:TR?= Ml\zV2FPT0WU
MHH-ES-1 NXLRWmw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwNkKwOlch|ryP NVjSPWx5W0GQR1XS
ES8 M1vKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwN{K0NVQh|ryP MnnTV2FPT0WU
NCI-H720 NYrDWVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\4TWM2OD1{LkKwOlk6KM7:TR?= M4PyNXNCVkeHUh?=
EW-3 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvmXZpMUUN3ME2yMlI4PTN2IN88US=> M2jFfXNCVkeHUh?=
D-566MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\JRplKSzVyPUKuOFQ2PjhizszN MkHDV2FPT0WU
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jDOWlEPTB;Mj64OFE4OyEQvF2= MoLqV2FPT0WU
ES5 NYrRSllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPrTWM2OD1{Lki4NVg6KM7:TR?= NIO3UXZUSU6JRWK=
COLO-684 M3XXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK5Ool2UUN3ME2zMlUyPjl4IN88US=> MWXTRW5ITVJ?
ML-2 M4\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7wTWM2OD1|Lk[wNFU5KM7:TR?= M1TXTXNCVkeHUh?=
MC-IXC NVTxc5A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX2bJFKSzVyPUOuOlM{QTNizszN MmXOV2FPT0WU
DB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwNkW0OFgh|ryP MoPzV2FPT0WU
HCC2218 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDudo9KSzVyPUOuO|MyODNizszN MVLTRW5ITVJ?
NCI-H510A MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwOEK3NlQh|ryP NHLWNFBUSU6JRWK=
NCI-H526 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLqOndtUUN3ME2zMlg3QTV6IN88US=> NGjHdWhUSU6JRWK=
MV-4-11 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftXGlEPTB;ND6xN|M{PCEQvF2= NGX2SlBUSU6JRWK=
PA-1 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwMkWyPUDPxE1? M1TEdXNCVkeHUh?=
EW-22 NEj3RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD12LkO1PFYh|ryP MYDTRW5ITVJ?
KASUMI-1 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3XY9KSzVyPUSuOFAyODlizszN NV3jSHRLW0GQR1XS
LU-139 NY\oOHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH72T5pKSzVyPUSuO|U5OjlizszN NFrLb5JUSU6JRWK=
SBC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjSOHFGUUN3ME20MlgxQTB6IN88US=> M4m3O3NCVkeHUh?=
H4 NUXqO5k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRwOEm0OFMh|ryP NFXsUYVUSU6JRWK=
EW-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorUTWM2OD13LkC4NFczKM7:TR?= NGTwbG9USU6JRWK=
NBsusSR MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzYT4k{UUN3ME21MlEzODV3IN88US=> MUXTRW5ITVJ?
RPMI-8226 NIDJOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;nWplKSzVyPUWuNVUzPDRizszN NIHpXG5USU6JRWK=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7RWVN4UUN3ME21MlIxODB4IN88US=> MXfTRW5ITVJ?
ES4 NVfBOmZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwNUGzPFkh|ryP NXH1Nm1wW0GQR1XS
GCT MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonLTWM2OD13LkW2PFU3KM7:TR?= NGrxZ3dUSU6JRWK=
NCI-H1048 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwOUeyO|Mh|ryP MUfTRW5ITVJ?
NCI-SNU-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTZwMEKyJO69VQ>? NYLqVY5EW0GQR1XS
ES7 NY\zW2U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fnSmlEPTB;Nj6wN|U4PyEQvF2= MX;TRW5ITVJ?
SW982 NX7zW4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLiTWM2OD14LkC5NVM4KM7:TR?= MYHTRW5ITVJ?
L-363 NETCXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDOIY6UUN3ME22MlM{QTd2IN88US=> NE\jSJhUSU6JRWK=
HT-1080 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tkd2lEPTB;Nj60PVY5OyEQvF2= MWrTRW5ITVJ?
HAL-01 NYrCNYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjNO3FKSzVyPU[uOVExQSEQvF2= M3Po[XNCVkeHUh?=
NB14 NXe2WVd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5NFdLUUN3ME22MlY1ODN7IN88US=> MnP2V2FPT0WU
EW-13 NUn6WZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfNbW5PUUN3ME22Mlc4PDJ2IN88US=> MoPEV2FPT0WU
NY NYjKcYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6dHNKSzVyPU[uPVQ3ODVizszN MlXmV2FPT0WU
NCI-SNU-5 M33mOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXflbY97UUN3ME23MlExPDN|IN88US=> NXvmPWcyW0GQR1XS
MS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GwZ2lEPTB;Nz6xO|Q6PCEQvF2= M1HHWHNCVkeHUh?=
EW-16 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnWTWM2OD15LkOxPFYyKM7:TR?= MWDTRW5ITVJ?
LU-65 NGTtU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPGT3pKSzVyPUeuOFg1OTdizszN MlvoV2FPT0WU
HGC-27 NV7Nd4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTdwN{KxO|Mh|ryP NV3wOnB6W0GQR1XS
CTB-1 NYHjWY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\N[mlEPTB;Nz63OlE4PSEQvF2= Ml3TV2FPT0WU
5637 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdwOUK4OkDPxE1? NEm4bWpUSU6JRWK=
U251 NUf4cItFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDxdnhKSzVyPUeuPVQxOTZizszN M2jpXnNCVkeHUh?=
HOS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HwRWlEPTB;OD6yN|AxPyEQvF2= M3XHPHNCVkeHUh?=
DOHH-2 M3LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRThwMkO1PEDPxE1? NVm2NpcyW0GQR1XS
EW-1 M3K4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\LbWlEPTB;OD6zNFA5QCEQvF2= NIXucmRUSU6JRWK=
BV-173 NIi5VY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[yTWM2OD16LkW1OVQh|ryP NWTpWFh1W0GQR1XS
8-MG-BA MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfoO|BKSzVyPUiuOlg6QDhizszN MXPTRW5ITVJ?
NB69 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRThwN{C5NlEh|ryP NF7yNYdUSU6JRWK=
NCI-H69 M3XBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zlb2lEPTB;OT65NFk3OSEQvF2= MkKyV2FPT0WU
RS4-11 NHKycmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFzLkKyNFgh|ryP M2TOenNCVkeHUh?=
ONS-76 NHrkcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjDVY1KSzVyPUGxMlI6PDdizszN NEHSdYZUSU6JRWK=
SF539 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1W2lEPTB;MUGuOFg5QSEQvF2= NGXPOpBUSU6JRWK=
HuO-3N1 M2XNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFzLkW3PVYh|ryP NVjydmpmW0GQR1XS
NCI-H1651 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W3N2lEPTB;MUKuN|EyPSEQvF2= MVjTRW5ITVJ?
KARPAS-45 M{TxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrvTWM2OD1zMj6zO|Yh|ryP MXnTRW5ITVJ?
SK-NEP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj4ZpRKSzVyPUGyMlQ3ODlizszN M33Vd3NCVkeHUh?=
LAMA-84 NV31PY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT2NHJKSzVyPUGzMlExQTVizszN NWrGcVQ3W0GQR1XS
NCI-H1155 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;wNIp5UUN3ME2xN{4zQDV4IN88US=> MnLIV2FPT0WU
CTV-1 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ITWM2OD1zMz60OFUh|ryP M4jmNnNCVkeHUh?=
QIMR-WIL Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF|Lke4NVQh|ryP MoHlV2FPT0WU
H9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXrTWM2OD1zMz64OFc2KM7:TR?= NFr4[5ZUSU6JRWK=
SK-MEL-1 M1fUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\nVY1KSzVyPUGzMlk{PDdizszN M2DSSHNCVkeHUh?=
HD-MY-Z NFXuU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:3N5Q2UUN3ME2xOE4xPjN5IN88US=> M2Kz[HNCVkeHUh?=
TI-73 NE\tbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXBTm1DUUN3ME2xOE4zOzV4IN88US=> MWrTRW5ITVJ?
JVM-3 M3\5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu5V4dKSzVyPUG1MlU4OTZizszN MYHTRW5ITVJ?
D-247MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrRU4dlUUN3ME2xOU42QTNizszN M1ezSXNCVkeHUh?=
VA-ES-BJ MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD1zNT62NFk4KM7:TR?= MlXxV2FPT0WU
NOS-1 NVnZNG05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF3Lk[1NlIh|ryP NYq3XWx{W0GQR1XS
MOLT-4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\XTWM2OD1zNj63OVIh|ryP M{HwdXNCVkeHUh?=
Mo-T Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXtTWM2OD1zNz6wPFQ6KM7:TR?= NX\XPI1NW0GQR1XS
NCI-H1770 NGTo[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF5LkG1OFMh|ryP NHi5bHpUSU6JRWK=
COLO-320-HSR NXLVc|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXadYtPUUN3ME2xO{4yQDJ5IN88US=> MlWyV2FPT0WU
TE-12 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvxTmNKSzVyPUG3MlcxPTRizszN NWHJdmVjW0GQR1XS
NCI-H82 NUXtfpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnHTWM2OD1zNz64O|I5KM7:TR?= NFvrbYxUSU6JRWK=
NEC8 M{LWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjtSoJSUUN3ME2xPE4yOzF4IN88US=> NH3VZ29USU6JRWK=
HSC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljPTWM2OD1zOD63OFE1KM7:TR?= MYPTRW5ITVJ?
NCI-H1092 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1zOD63OVk2KM7:TR?= MVPTRW5ITVJ?
NCI-H292 M3fIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfFO5J7UUN3ME2xPU4xPDh7IN88US=> MlHOV2FPT0WU
L-428 NEnqSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfGOVNoUUN3ME2xPU42PTlizszN NITnUmpUSU6JRWK=
LU-134-A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITvNXNKSzVyPUG5MlU4OiEQvF2= NULhdI0{W0GQR1XS
GI-ME-N NFPCZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\SdWlEPTB;MUmuOVc1PyEQvF2= M3HBSHNCVkeHUh?=
ALL-PO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyTWM2OD1zOT61PVczKM7:TR?= NIfDTZFUSU6JRWK=
D-283MED MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpWW1KSzVyPUG5MlkyPSEQvF2= MYjTRW5ITVJ?
D-423MG NXjRU24yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ETWM2OD1zOT65PVY4KM7:TR?= MmDaV2FPT0WU
CAKI-1 M1zpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17aSWlEPTB;MkCuNlIyQSEQvF2= MX;TRW5ITVJ?
ETK-1 NG\mR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJyLkK2NVUh|ryP MY\TRW5ITVJ?
G-402 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TPTWlEPTB;MkCuOVM{PCEQvF2= MnzRV2FPT0WU
HL-60 NHnXVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXSTWM2OD1{MT6xOlE{KM7:TR?= Ml\YV2FPT0WU
A2058 NYHZNpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NdZhKSzVyPUKxMlQ1PzdizszN MnPCV2FPT0WU
CHP-212 M3rIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S4eWlEPTB;MkGuPVA2OSEQvF2= NVrObYpUW0GQR1XS
KY821 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrpN5JKSzVyPUKxMlk4PSEQvF2= MV7TRW5ITVJ?
TYK-nu Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ{LkC2OVEh|ryP MVPTRW5ITVJ?
JVM-2 M4[zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnZfo1KUUN3ME2yNk4zQTh|IN88US=> MoPYV2FPT0WU
KU812 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPNGlEPTB;MkKuO|MyOiEQvF2= MYTTRW5ITVJ?
MKN28 M32ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ{LkmwNVUh|ryP NIq4bnBUSU6JRWK=
ECC10 M3nmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Vc2lEPTB;MkOuO|QyKM7:TR?= NYnTS2dsW0GQR1XS
BHT-101 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yTWM2OD1{ND6wNFA5KM7:TR?= Ml3WV2FPT0WU
DU-4475 NVyzUYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUSXhUUUN3ME2yOE4{OzN5IN88US=> MUnTRW5ITVJ?
769-P MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTReFJKSzVyPUK0Mlg1PjZizszN NUjIcYs{W0GQR1XS
HEC-1 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv6TWM2OD1{NT60OFUh|ryP NYXTbXZMW0GQR1XS
MOLT-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMSWlEPTB;MkWuOVM{OSEQvF2= MVHTRW5ITVJ?
8505C MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofiTWM2OD1{Nj60PVc4KM7:TR?= NHLndnhUSU6JRWK=
GB-1 M{C5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkeGl7UUN3ME2yOk44OTd4IN88US=> MkjQV2FPT0WU
SF126 M2\RSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWbGlEPTB;Mk[uO|Y1QCEQvF2= NYHrS4JkW0GQR1XS
A4-Fuk MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX0TWM2OD1{Nz6xNlcyKM7:TR?= MWnTRW5ITVJ?
OVCAR-8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfs[4dKSzVyPUK3MlE2OzlizszN MWfTRW5ITVJ?
NCI-H1304 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGyTWM2OD1{Nz61OEDPxE1? MWjTRW5ITVJ?
GR-ST MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTITWM2OD1{OD6wOFch|ryP NYjufoU3W0GQR1XS
G-401 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zJUGlEPTB;MkiuOVA6PiEQvF2= NFfDXY5USU6JRWK=
LXF-289 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknLTWM2OD1{OD61OlUyKM7:TR?= NXq0UohzW0GQR1XS
DBTRG-05MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLhVXFnUUN3ME2yPE46OjB2IN88US=> MmLxV2FPT0WU
YKG-1 NYPsPYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fPdWlEPTB;MkmuPFY5KM7:TR?= M1;SXXNCVkeHUh?=
GAMG MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTmRmhzUUN3ME2yPU46QTNizszN Mnn2V2FPT0WU
HCT-116 M3vxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNyLkC1OFgh|ryP MWTTRW5ITVJ?
S-117 M3K2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PIVWlEPTB;M{GuNlI2PyEQvF2= NYG4VXoyW0GQR1XS
NCI-H1693 NVnnS2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfIW3pyUUN3ME2zN{43PTR{IN88US=> NV3FNGZ7W0GQR1XS
A427 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorrTWM2OD1|Mz65PVc3KM7:TR?= M3Hrd3NCVkeHUh?=
HT-29 NY\HOnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[xPIdKSzVyPUO0MlYxOzJizszN MlXOV2FPT0WU
P12-ICHIKAWA MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfEdZQ{UUN3ME2zOE44PDlzIN88US=> M2DFWHNCVkeHUh?=
CAL-51 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN3LkC3NFkh|ryP NXPic4JtW0GQR1XS
Ramos-2G6-4C10 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnexTWM2OD1|NT6yOFI2KM7:TR?= MWXTRW5ITVJ?
SCH M1uxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnIe5dKSzVyPUO2MlQyPzRizszN NYnDSotCW0GQR1XS
SK-MEL-24 NWX1S|VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTN4LkmwOFQh|ryP NWCzeYFPW0GQR1XS
SW1573 NWPNWpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN6LkeyNVYh|ryP NWjWWodGW0GQR1XS
BALL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnzfodKSzVyPUO5MlIyOjlizszN Mn\vV2FPT0WU
BE-13 NF3MW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXnN4dKSzVyPUO5MlMzQSEQvF2= MVHTRW5ITVJ?
GI-1 NVO2N|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInEZmFKSzVyPUO5Mlg3PDdizszN MVrTRW5ITVJ?
GOTO M{eyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN7LkmxN|kh|ryP NEX3TnlUSU6JRWK=
A673 NXj4PWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qyRmlEPTB;NEGuNFM1OyEQvF2= MV3TRW5ITVJ?
KG-1 NVS2PVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OTWM2OD12Mz6zPVQh|ryP Ml7sV2FPT0WU
GP5d M3vvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR2LkC2OlYh|ryP NFPRVnRUSU6JRWK=
MFM-223 M{fL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR2LkGyNlgh|ryP NULwO4xmW0GQR1XS
OAW-42 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR2LkK2OFMh|ryP NUnWPGhRW0GQR1XS
C8166 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHi[pV4UUN3ME20OU4xQDJ{IN88US=> NYTMXot2W0GQR1XS
LU-99A NX;Re3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR4LkGzNlIh|ryP MVvTRW5ITVJ?
NCI-H23 NXXUXG04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTR4LkG3PFUh|ryP MkLyV2FPT0WU
HO-1-N-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHYTWM2OD12Nz6wPVk5KM7:TR?= MUfTRW5ITVJ?
A3-KAW Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ZTWM2OD12Nz6xNFA4KM7:TR?= MmTyV2FPT0WU
CGTH-W-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPOZZkxUUN3ME20O{42ODZ7IN88US=> NVzycmYyW0GQR1XS
DJM-1 NH[zfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR5LkW0NVMh|ryP M2\MNnNCVkeHUh?=
A101D Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXt[JdKSzVyPUS3MlY{PTdizszN NVjkVm5tW0GQR1XS
BB30-HNC NHviRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTSNm9NUUN3ME20PE4{ODd{IN88US=> NHPKSGhUSU6JRWK=
T98G MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR6LkS2N|Mh|ryP MYTTRW5ITVJ?
NCI-H1573 NUfBSGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR7LkS0OlIh|ryP M1rQOnNCVkeHUh?=
MEG-01 NVnQcpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXCeWN5UUN3ME20PU44PDFzIN88US=> Mn\IV2FPT0WU
WM-115 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsUXNKSzVyPUS5MlkzOjJizszN NH74c|ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (197.94 mM) warming
Water 0.002 mg/mL (0.0 mM)
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID